Schade – dieser Artikel ist leider ausverkauft. Sobald wir wissen, ob und wann der Artikel wieder verfügbar ist, informieren wir Sie an dieser Stelle.
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
A review of therapeutic antibodies which have commercial potential. It discusses PCR cloning of Igs, immortalization by gene transfer, scale up production, infectious diseases, viruses, bacteria, parisites, inflammation/immunology, blood grouping, cells, cytokines, tumours and MDR.
Andere Kunden interessierten sich auch für
- Immunology of Endometriosis98,99 €
- Therapeutic Antibodies74,99 €
- Progress in Cancer Immunotherapy110,99 €
- Helicobacter pylori37,99 €
- Louis J. CataniaThe Paradox of the Immune System115,99 €
- Maternal Immunization84,99 €
- Encyclopedia of Medical Immunology330,99 €
-
A review of therapeutic antibodies which have commercial potential. It discusses PCR cloning of Igs, immortalization by gene transfer, scale up production, infectious diseases, viruses, bacteria, parisites, inflammation/immunology, blood grouping, cells, cytokines, tumours and MDR.
Produktdetails
- Produktdetails
- Verlag: Palgrave Macmillan / Palgrave Macmillan UK / Springer Palgrave Macmillan
- Artikelnr. des Verlages: 978-1-349-11896-0
- 1st ed. 1990
- Seitenzahl: 369
- Erscheinungstermin: 1. Januar 1990
- Englisch
- Abmessung: 229mm x 152mm x 22mm
- Gewicht: 563g
- ISBN-13: 9781349118960
- ISBN-10: 1349118966
- Artikelnr.: 44459712
- Verlag: Palgrave Macmillan / Palgrave Macmillan UK / Springer Palgrave Macmillan
- Artikelnr. des Verlages: 978-1-349-11896-0
- 1st ed. 1990
- Seitenzahl: 369
- Erscheinungstermin: 1. Januar 1990
- Englisch
- Abmessung: 229mm x 152mm x 22mm
- Gewicht: 563g
- ISBN-13: 9781349118960
- ISBN-10: 1349118966
- Artikelnr.: 44459712
The use of in vitro immunization, cloning of variable regions and scid mice for the production of human monoclonal antibodies; construction of recombinant therapeutic monoclonal antibodies; antibody-mediated cancer diagnosis and therapy; current status and future perspectives of chemoimmunoconjugates for the treatment of cancer; gangliosides as targets for monoclonal antibody therapy of cancer; mouse antibodies to carcinomas; therapeutic implication of monoclonal antibodies against multidrug resistant tumour cells; radioimmunotherapy with 90yttrium-anti-idiotype monoclonal antibody; immunoconjugates of a protein synthesis inhibiting drug; human monoclonal anti-idiotypic antibodies against a murine monoclonal antibody (Mab17-1A) as an anti-tumour vaccine; uses of human monoclonal antibodies to human cytomegalovirus and varicella-zoster virus; development of a human monoclonal antibody against cytomegalovirus with the aim of passive immunotherapy; characterization of human anti-cytomegalovirus monoclonal antibodies; immunoprotective capacities of human and murine monoclonal antibodies recognizing serotype specific and common determinants of gram-negative bacteria; pharmocokinetics of xomen TM-E5 in animals and humans; radomized placebo-controlled study of E5 monoclonal antiendotoxin antibody; human monoclonal antibodies against human red blood cells; CD7 monoclonal antibodies; large scale production of monoclonal antibodies; European regulatory issues.
The use of in vitro immunization, cloning of variable regions and scid mice for the production of human monoclonal antibodies; construction of recombinant therapeutic monoclonal antibodies; antibody-mediated cancer diagnosis and therapy; current status and future perspectives of chemoimmunoconjugates for the treatment of cancer; gangliosides as targets for monoclonal antibody therapy of cancer; mouse antibodies to carcinomas; therapeutic implication of monoclonal antibodies against multidrug resistant tumour cells; radioimmunotherapy with 90yttrium-anti-idiotype monoclonal antibody; immunoconjugates of a protein synthesis inhibiting drug; human monoclonal anti-idiotypic antibodies against a murine monoclonal antibody (Mab17-1A) as an anti-tumour vaccine; uses of human monoclonal antibodies to human cytomegalovirus and varicella-zoster virus; development of a human monoclonal antibody against cytomegalovirus with the aim of passive immunotherapy; characterization of human anti-cytomegalovirus monoclonal antibodies; immunoprotective capacities of human and murine monoclonal antibodies recognizing serotype specific and common determinants of gram-negative bacteria; pharmocokinetics of xomen TM-E5 in animals and humans; radomized placebo-controlled study of E5 monoclonal antiendotoxin antibody; human monoclonal antibodies against human red blood cells; CD7 monoclonal antibodies; large scale production of monoclonal antibodies; European regulatory issues.